Drug-Eluting Nasal Implants: Formulation, Characterization, Clinical Applications and Challenges

Pharmaceutics

Ankit Parikh²  Utkarshini Anand²  Malachy C. Ugwu²  Tiam Feridooni²  Emad Massoud¹ 

[1] Queen Elizabeth II (QEII) Health Sciences Centre, 1278 Tower Road, Halifax, NS B3H 2Y9, Canada; E-Mail:;Biopharmaceutics and Drug Delivery Lab, College of Pharmacy, 5968 College Street, P.O. Box 15000, Halifax, NS B3H 4R2, Canada; E-Mails:

关键词: nasal;    sinuses;    rhinosinusitis;    stents;    implants;    inserts;    sustained-release;   

DOI  :  10.3390/pharmaceutics6020249

来源: mdpi

【 摘 要 】

Chronic inflammation and infection of the nasal sinuses, also referred to as Chronic Rhinosinusitis (CRS), severely affects patients’ quality of life. Adhesions, ostial stenosis, infection and inflammation relapses complicate chronic sinusitis treatment strategies. Drug-eluting stents, packings or implants have been suggested as reasonable alternatives for addressing these concerns. This article reviewed potential drug candidates for nasal implants, formulation methods/optimization and characterization methods. Clinical applications and important considerations were also addressed. Clinically-approved implants (Propel™ implant, the Relieva stratus™ MicroFlow spacer, and the Sinu-Foam™ spacer) for CRS treatment was an important focus. The advantages and limitations, as well as future considerations, challenges and the need for additional research in the field of nasal drug implant development, were discussed.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.